|
gptkbp:instanceOf
|
gptkb:drug
antineoplastic agent
|
|
gptkbp:approvalYear
|
1975
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01AX04
|
|
gptkbp:CASNumber
|
4342-03-4
|
|
gptkbp:category
|
antineoplastic agent
prodrug
imidazole carboxamide
|
|
gptkbp:contraindication
|
hypersensitivity to dacarbazine
|
|
gptkbp:discoveredBy
|
gptkb:Yale_University
|
|
gptkbp:eliminationHalfLife
|
5 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C6H10N6O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dacarbazine
|
|
gptkbp:KEGGID
|
gptkb:D00293
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
antineoplastic agent
DNA synthesis inhibitor
|
|
gptkbp:MeSH_ID
|
D003616
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL137
4445392
DB00851
5281007
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
anorexia
myelosuppression
flu-like symptoms
|
|
gptkbp:synonym
|
gptkb:DTIC
|
|
gptkbp:UNII
|
6QXW8STU1B
|
|
gptkbp:usedFor
|
treatment of melanoma
treatment of Hodgkin lymphoma
|
|
gptkbp:bfsParent
|
gptkb:Sigma-Tau_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
8
|